Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.63% year-on-year.
Fairly Valued
The company’s latest PE is -69.24, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 48.71M shares, increasing 6.07% quarter-over-quarter.
Held by Ron Baron
Star Investor Ron Baron holds 534.99K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.75.